Roivant Sciences Ltd. reported a net loss attributable to the company of $223.4 million for the three months ended June 30, 2025, compared to a net income of $95.3 million in the same period of the previous year. The loss from continuing operations, net of tax, was $273.9 million, a notable increase from the loss of $31.6 million reported for the same period in 2024. There was no income from discontinued operations in the current quarter, compared to $89.2 million in the previous year. The basic and diluted net loss per common share was $0.33, contrasting with a net income per share of $0.13 in the same quarter the previous year. The weighted average shares outstanding were 680.3 million basic and 735.8 million diluted for the current period, compared to 680.3 million basic and 781.6 million diluted in the previous period. Roivant reported consolidated cash, cash equivalents, restricted cash, and marketable securities totaling $4.5 billion as of June 30, 2025, which supports the company's cash runway into profitability. The company has completed its initial $1.5 billion share repurchase program and announced an additional buyback program. CEO Matt Gline highlighted ongoing clinical progress and preparations for the potential launch of brepocitinib, which is anticipated to benefit patients with high unmet need.